INDONESIA BREAST CANCER MODEL HEALTH RELATED QUALITY OF LIFE FOR THE MEASUREMENT OF QUALITY OF LIFE AND UTILITY COST ANALYSIS OF BREAST CANCER PATIENTS IN RS CANCER Operable DHARMAIS
ABSTRACT: The use of chemotherapy protocols with early stage breast cancer in the Cancer Hospital Dharmais (RSKD) mostly uses chemotherapy protocol- Fluorouracil-Adriamicyn Cyclophosphamid (FAC) and taxane base. The effectiveness of the two therapies is only measured physical output such as recovering from illness, mortality, morbidity and recurrence rate. However the quality of life must also be considered. Meanwhile, quality of life measurement tool does not accommodate the existing Indonesian culture. This study aimed to obtain a model of health status measurements that lead to quality of life for Indonesian breast cancer patients (INA-BCHRQoL) and applied to the cost utility analysis in patients with early-stage breast cancer who obtain FAC chemotherapy and chemotherapy Taxanes-based. The design of this study is exploratory and confirmatory. Respondents were all patients with breast cancer stage I-IIIA who had surgery, adjuvant chemotherapy FAC and Taxanes based, and irradiated began in January 2011- December 2012. Cost calculation includes direct and indirect costs. Measurement of quality of life questionnaire done by mapping attributes to EQ5D Calculator. The results showed there was no significant difference between the scores of quality of life and utility in respondents who received FAC chemotherapy and Taxanes based. There are significant differences in the chemotherapy group Taxanes utility. FAC chemotherapy is more cost effective than taxanes. INABCHRQoL can be used to measure the status of the quality of life of breast cancer patients in Indonesia.
